Potential Therapeutic Effects of Psilocybin

Classic psychedelics such as psilocybin have a long history of sacramental use in indigenous cultures and drew intense scientific interest in the mid-twentieth century. Between the 1950s and mid-1960s, more than 1,000 clinical papers involving roughly 40,000 patients were published, producing early, though methodologically limited, evidence that these compounds might aid end-of-life psychiatric distress and addiction. Political backlash and regulatory changes largely halted human research for decades, but interest has resumed in the twenty-first century, with psilocybin becoming the principal focus of recent clinical work. This review examines modern therapeutic research on psilocybin, emphasising two potential indications: cancer-related psychiatric distress and addiction. It summarises clinical trials, pilot studies, observational reports and mechanistic work, and highlights safety considerations and the structured therapeutic model commonly employed in clinical research with psilocybin.

Johnson and colleagues present a narrative review of contemporary psilocybin research rather than a systematic review with a reported search strategy. The extracted text describes and synthesises findings from a range of study types, including double-blind, placebo-controlled crossover trials in cancer patients, small open-label pilot trials (for treatment-resistant depression, tobacco and alcohol dependence), case series and survey data (notably for cluster headaches), a small OCD pilot, and neurobiological investigations such as resting-state functional MRI studies. The review integrates clinical outcomes, safety data and theoretical biological mechanisms. The extracted text does not report explicit methods for literature identification, such as databases searched, date ranges, inclusion/exclusion criteria, study selection procedures, or formal risk-of-bias assessment. Consequently, it is not possible from the provided extraction to determine how comprehensively the literature was captured or whether study quality was systematically graded. Instead, the paper appears to select and discuss representative modern clinical studies and related earlier work to illustrate therapeutic potential and remaining gaps. A prominent feature of the review is description of the therapeutic model used in psilocybin studies: careful participant screening (notably excluding current psychosis or high cardiovascular risk), preparatory sessions, supervised dosing sessions with interpersonal support and encouragement of internal focus, and post-session integration. Safety and outcome data reported in the review derive from trials and pilot studies that used these structured procedures.

Pharmacology and safety profile: Psilocybin is a naturally occurring tryptamine found in many mushroom species and is a prodrug converted in vivo to psilocin, which acts primarily as a 5-HT2A receptor agonist. The compound is described as having low physiological toxicity and low abuse liability; nonhuman self-administration studies show only marginal levels of reinforcing behaviour. Transient increases in blood pressure and dose-related post-session headaches have been reported, but serious drug-related adverse events were not attributed to psilocybin in the clinical studies reviewed. Cancer-related psychiatric distress: Three controlled trials in patients with cancer-related anxiety and/or depression are summarised. A small double-blind, placebo-controlled crossover study in 12 patients used 0.2 mg/kg psilocybin versus niacin and found nonsignificant trends favouring psilocybin for short-term reductions in depression (BDI) and anxiety (STAI); however, anxiety was reduced at 3 months and depression was significantly reduced at 6 months compared with baseline. A larger double-blind crossover study in 51 patients compared higher doses (~0.31 or ~0.43 mg/kg) with very-low-dose psilocybin (~0.014 or ~0.043 mg/kg) and reported numerous improved clinical outcomes at 5 weeks and large, persistent reductions on the Hamilton Anxiety Rating Scale, STAI, Hamilton Depression Rating Scale and BDI at 6 months. Approximately 80% of participants at 6 months showed clinically significant decreases in depressed mood and anxiety and about 60% met remission criteria. A third crossover trial in 29 patients (0.3 mg/kg vs niacin) similarly found significant improvements before the crossover and persisting anxiolytic and antidepressant effects at about 6 months, with response/remission rates of roughly 60% to 80%. Across these studies, greater subjective mystical-type experiences during sessions were associated with larger and longer-lasting clinical benefits. No serious adverse events were attributed to psilocybin in these cancer trials. Treatment-resistant depression: A small open-label pilot study in 12 patients with treatment-resistant major depression administered 10 mg oral psilocybin in the first session and 25 mg in a second session one week later. Depressive symptoms (Quick Inventory of Depressive Symptoms, BDI and others) and anxiety (STAI) were significantly reduced at 1 week and at 3 months compared with baseline. All participants showed some reduction at 1 week; by standard BDI remission criteria, 8 of 12 met complete remission at an early time point and 5 of 12 remained in remission at the 3-month follow-up. No unexpected or serious adverse events were reported. Addiction: Historical studies of LSD and observational data suggested possible benefits for alcoholism, and a meta-analysis of six randomized LSD studies (total n = 536) reported an odds ratio favouring LSD for reduced alcohol misuse at initial follow-up. Modern psilocybin pilot studies are preliminary but promising. In an open-label smoking cessation pilot (n = 15) combining cognitive behavioural therapy and psilocybin, participants received ~0.29 mg/kg on a target quit date and optional additional doses of ~0.43 mg/kg at 2 and 8 weeks. Biologically verified abstinence rates were 12 of 15 (80%) at 6 months, 10 of 15 (67%) at 12 months, and 9 of 12 (75%) at an average 2.5-year follow-up. Higher mystical-type experience scores correlated with abstinence and reduced craving. In a small alcohol-dependence pilot (n = 10) embedded in a 12-week motivational enhancement programme, initial 0.3 mg/kg and, for some, 0.4 mg/kg psilocybin sessions were followed by significant reductions in self-reported alcohol use that persisted to 36-week follow-up; days drinking fell from about 40% at baseline to under 20% at follow-up, and greater mystical-type experiences correlated with larger decreases in consumption. No serious adverse events were reported in these addiction studies. The authors note that these open-label findings require confirmation in larger randomized trials, which are underway. Other disorders and case reports: A pilot study in nine patients with obsessive-compulsive disorder using escalating doses (0.025–0.3 mg/kg) observed substantial symptom reduction during at least one session for all participants, but only one participant showed long-term improvement at 6 months; similar effects across very low and higher doses raise concern about expectancy/placebo influences. For cluster headaches, a case series of 53 self-medicating patients and a survey of 496 individuals reported that psilocybin-containing mushrooms and related psychedelics sometimes terminated or prevented cluster headaches, including reports of efficacy at doses without noticeable psychoactive effects; evidence is uncontrolled and based largely on self-medication. An open-label pilot of the non-psychoactive analogue 2-bromo-LSD showed promise, which, if confirmed, could reduce the clinical appeal of psychoactive psilocybin for this indication. Biological mechanisms: The review reiterates the central role of 5-HT2A agonism in acute effects but notes that this does not fully explain therapeutic outcomes. Resting-state fMRI studies show acute alterations in brain network activity, including decreased connectivity within the default mode network. The authors advance a hypothesis that psilocybin may transiently destabilise brain networks, creating a plastic state during which psychotherapeutic context helps shape persistent network changes; however, no biological markers have yet been shown to distinguish responders from non-responders.

Johnson and colleagues interpret the assembled evidence as indicating substantial therapeutic promise for psilocybin, particularly for cancer-related psychiatric distress where three randomized, placebo-controlled trials have reported large, enduring reductions in depression and anxiety following a single active administration. The magnitude and persistence of effects at 6 months in those trials are highlighted as notable and relatively unprecedented within psychiatry. Outside the cancer context, the open-label treatment-resistant depression study provides preliminary evidence that sustained antidepressant effects may generalise beyond cancer-related distress. Addiction research is described as encouraging but earlier in development; two small open-label pilots for tobacco and alcohol dependence produced high abstinence or reduced use rates and established safety in carefully controlled settings, motivating larger randomized trials now in progress. Across indications, the authors emphasise a consistent association between intensity of subjective mystical-type experiences during sessions and better clinical outcomes, suggesting psychological processes play an important role in therapeutic response. The authors acknowledge important limitations in the existing literature: many studies have small sample sizes, some use open-label designs or lack active comparators, and expectancy or placebo effects cannot be ruled out in several cases (notably the OCD and self-medication reports). They also note the scarcity of biological markers that predict or explain therapeutic success. Safety conclusions are qualified by the fact that trials have used careful screening and structured therapeutic support, and that individuals at risk for psychosis or significant cardiovascular disease were routinely excluded. Finally, the authors call for larger, rigorous trials and for government funding to facilitate thorough evaluation of efficacy, safety and mechanisms, and recommend that any clinical implementation mirror the screening, preparation, monitoring and integration procedures used in research to optimise benefits and minimise risks.

The authors conclude that modern research provides considerable reason for optimism about psilocybin as a therapeutic modality. Evidence is strongest for cancer-related psychiatric distress, where randomized trials have shown substantial and durable anxiolytic and antidepressant effects after single-dose administration. Early open-label studies in treatment-resistant depression and addiction also suggest potential utility, warranting larger randomized trials. Johnson and colleagues argue that if further trials confirm safety and persisting efficacy, psilocybin could become an approved medicine, but they stress that regulatory frameworks should require the careful clinical procedures used in research. Greater public research funding is recommended to enable cautious, scholarly investigation into clinical applications and mechanisms.